SGP Company Profile and Key Details

Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $62.00 to $37.00. The high target offers 153.58% upside. The low target suggests 51.33% downside. The mean target is $45.00. This offers 84.05% upside.

SpyGlass Pharma, Inc. Common Stock (NASDAQ:SGP) closed at $24.34 USD, losing -$0.11 (-0.45%) from the previous close of $24.45. The stock is currently mid-range between its 52-week high and low $20.15 and $32.44. With a market capitalization of about $813.60 million, SpyGlass Pharma, Inc. Common Stock is classified as a small-cap and shows lower-than-market volatility (beta ~0.00). Key stats such as the average daily volume over the past year has been around 136.68 thousand shares, volume is running light vs its 52-week average. Headquartered in Aliso Viejo, CA, SpyGlass Pharma, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Patrick H. Mooney, the company employs approximately 1,489 people and listed since January 08, 2008. SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Our AI price prediction model suggests that SpyGlass Pharma, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.63%, with price expected at $22.83 by May 05, 2026, within a range of $21.13 to $24.47 3-Month Outlook: Projected fall of -25.97%, reaching $18.10 by July 20, 2026, with a range of $17.89 to $18.31. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by April 21, 2027, within a range of $0.00 to $0.00.

currently trading near 52-week highs band. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $45.00, suggesting 84.05% upside. Our AI forecast model points to short-term weakness (-6.63% over two weeks), a medium-term fall (-25.97% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.